Application of nanotherapy in cardiovascular diseases featuring novel pharmacological mechanisms and drug delivery strategies.

Authors

Jing Yang

Published in

Discover nano. Volume 21. Issue 1. Aug 11, 2026. Epub Aug 11, 2026.

Abstract

Cardiovascular diseases (CVDs) remain the leading cause of death globally. However, conventional pharmacotherapy is often limited by poor targeting, low bioavailability, and systemic adverse reactions. Nanoformulations, including liposomes, polymeric nanoparticles, inorganic nanocarriers, biomimetic systems, and lipid-based carriers, have emerged as transformative platforms that enhance drug solubility, stability, and lesion-specific delivery. This review systematically summarizes the structural features, drug-loading mechanisms, and release strategies of these nanocarriers in major cardiovascular disease indications, such as atherosclerosis, myocardial infarction, hypertension, heart failure, and coronary artery disease. Relevant studies on nanoparticles loaded with Western drugs and traditional Chinese medicine monomers are discussed within a unified framework. Furthermore, this review addresses the limitations of endothelial permeability in cardiovascular tissues, translational barriers, and future directions for clinical implementation.

PMID:
42579251
Bibliographic data and abstract were imported from PubMed on 11 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.